期刊
NEUROIMMUNOMODULATION
卷 19, 期 4, 页码 201-208出版社
KARGER
DOI: 10.1159/000334095
关键词
Antidepressants; Cytokines; Experimental autoimmune encephalomyelitis; Fluoxetine; Multiple sclerosis
资金
- Natural Science Foundation of the Guangdong Province [1045-1051-5010-05748]
- Youth Research Foundation of the Nanfang Hospital [2009C025]
Objective: This study was carried out to clarify the effects of the antidepressant fluoxetine, a selective serotonin reuptake inhibitor, for its potential use in autoimmune diseases like multiple sclerosis in a rat model of experimental autoimmune encephalomyelitis (EAE). Methods:The rat EAE model was induced by subcutaneous injection of guinea pig spinal cord homogenate. Rats received fluoxetine via daily intragastric administration, starting 2 weeks prior to immune induction (fluoxetine pretreatment). Clinical scores and pathological changes in EAE rats were analyzed. Changes in serum cytokine levels were assessed by ELISA. Results: Fluoxetine pretreatment significantly promoted remission in EAE. Histologically, fluoxetine-induced neuroprotection was accompanied by reductions in inflammatory foci and in the degree of demyelination in the spinal cord of EAE rats. The increase in serum IFN-gamma in the EAE model was also suppressed by fluoxetine administration. Conclusions: These findings suggest that the prophylactic use of fluoxetine can relieve symptoms during remission in the acute EAE model, and these neuroprotective effects are associated with its anti-inflammatory effects. Copyright (C) 2012 S Karger AG, Basel
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据